Prostate Cancer Clinical Trial
Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer
Summary
RATIONALE: Vaccines made from tumor cells may help the body build an effective immune response to kill tumor cells.
PURPOSE: This randomized phase II trial is studying vaccine therapy to see how well it works compared with a placebo in treating patients with stage D0 prostate cancer.
Full Description
OBJECTIVES:
Primary
To determine whether ONY-P1 vaccine can increase the time to PSA-defined progression in patients with androgen-dependent stage D0 prostate cancer.
Secondary
To evaluate all toxicities related to ONY-P1 vaccine.
To compare the immunologic response in patients treated with ONY-P1 vaccine vs placebo.
To evaluate PSA kinetics (doubling time/velocity) of treatment.
To evaluate time to testosterone recovery following limited androgen ablation.
OUTLINE: Patients are stratified according to estimated PSA doubling time (< 12 months vs ≥ 12 months).
Patients receive goserelin subcutaneously once. Approximately 3 months later, patients are randomized to 1 of 2 treatment arms.
Arm I: Patients receive ONY-P1 vaccine with BCG intradermally on days 1 and 15. Patients then receive ONY-P1 vaccine alone on day 29 and then every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
Arm II: Patients receive placebo vaccine intradermally on days 1, 15, and 29 and then every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
After completion of study therapy, patients are followed periodically for up to 15 years.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Histopathological documentation of prostate cancer
If no pathologic specimen is available, patients may enroll on study with a pathologist's report showing a histologic diagnosis of prostate cancer and a clinical course consistent with the disease
Biochemical progression, as defined by the following:
A rise in PSA of ≥ 2 ng/mL above the nadir (for patients previously treated with definitive radiotherapy or cryotherapy)
Two consecutive rises in PSA > 0.3 ng/mL (for patients previously treated with radical prostatectomy)
PSA ≤ 20 ng/mL
Testosterone ≥ lower limit of normal
Negative CT scan and bone scan for metastatic prostate cancer
No clinically active brain metastases
PATIENT CHARACTERISTICS:
ECOG performance status of 0-1
Life expectancy ≥ 6 months
Granulocyte count ≥ 1,500/mm³
Platelet count ≥ 100,000/mm³
Hemoglobin ≥ 10 g/dL
Bilirubin ≤ 1.5 mg/dL OR total bilirubin ≤ 3.0 mg/dL (in patients with Gilbert's syndrome)
AST and ALT ≤ 2.5 times upper limit of normal
No other active malignancies within the past 60 months (with the exception of nonmelanoma skin cancer or carcinoma in situ of the bladder)
No life-threatening illnesses
No immunocompromised status due to any of the following:
HIV positivity
Active autoimmune diseases, such as Addison's disease, Hashimoto's thyroiditis, systemic lupus erythematosus, Sjögren syndrome, scleroderma, myasthenia gravis, Goodpasture syndrome, or active Grave's disease
Patients with a history of autoimmunity that has not required systemic immunosuppressive therapy or does not threaten vital organ function, including CNS, heart, lungs, kidneys, skin, or gastrointestinal tract, will be allowed
Other immunodeficiency diseases or iatrogenic immunodeficiency from drugs
No other serious medical illness that would interfere with the patient's ability to carry out the treatment program
No documented contraindication (allergy or severe reaction to BCG)
PRIOR CONCURRENT THERAPY:
See Disease Characteristics
Recovered from all prior therapy, including surgery and radiotherapy (no toxicity ≥ grade 2)
No prior chemotherapy
No concurrent topical steroids (including steroid eye drops) or systemic steroids
Nasal or inhaled steroid use is permitted
No concurrent medications used for urinary symptoms, including 5-alpha reductase inhibitors (finasteride and dutasteride)
No concurrent alternative medications known to alter PSA (e.g., phytoestrogens or saw palmetto)
No other concurrent hormonal therapy
No other concurrent anticancer treatment, including chemotherapy, systemic glucocorticoids, radiotherapy, major surgical procedures for prostate cancer, or nonprotocol-related immunotherapy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Bethesda Maryland, 20892, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.